Genmab — December 2020
-
JNJ-7957 er det samme som teclistamab. peter's link er det prækliniske studie, som har ført videre til klinisk studie i dara+teclistamab i MM https://www.clinicaltrials.gov/ct2/show/NCT04108195?term=daratumumab+teclistamab&draw=2&rank=1
-
Var det leukemi udover MM som de ville afprøve hexa-cd38 imod?
-
Fra aftalen med Janssen: HexaBody-CD38 could be superior to daratumumab for certain tumor cell types and may expand and extend the promise of CD38-targeted therapies for more patients with multiple myeloma, lymphoma, leukemia, and potentially beyond.
-
Ja klart
-
-
Dr Mark Wildgust: Updated APOLLO Trial Results Confirm Daratumumab Safety in Multiple Myeloma https://www.ajmc.com/view/dr-mark-wildgust-updated-apollo-trial-results-confirm-daratumumab-safety-in-multiple-myeloma - ONLY
5% of patients had infusion-related reactions in the APOLLO study, and all of those were grade 1/grade 2. So real confirmation that subcu dara is well tolerated. -
https://genmab-at-ash-2020.com/ genmab-at-ash-2020
-
a bit strange when you look at the pipeline, poster on the right or https://virtualboothdemo.s3.amazonaws.com/Genmab/Content/PDFs/ash/I FINAL PIPELINE.pdf , it shows HexaBody CD38 in development phase I/II
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind